Phase II Study of IGEV Followed by Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin Lymphoma.
The standard treatment in patients with refractory or relapsed Hodgkin lymphoma is salvage
chemotherapy followed by autologous transplantation for responsive patients. However, the
standard of salvage chemotherapy remains uncertain. This study is to evaluate the efficacy
and safety of IGEV regimen in a single-center basis.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Complete response rate
6 weeks
No
Ye Guo, MD
Principal Investigator
Fudan University
China: Ethics Committee
LMTG 11-02
NCT01333605
April 2011
June 2014
Name | Location |
---|